$542 Million is the total value of Samsara BioCapital, LLC's 44 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 39.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NKTX | Nkarta, Inc. | $66,942,000 | -46.5% | 2,034,703 | 0.0% | 12.35% | -1.8% | |
| KDNY | Chinook Therapeutics Inc | $49,237,000 | -2.0% | 3,168,388 | 0.0% | 9.08% | +79.7% | |
| FMTX | Buy | Forma Therapeutics Holdings, Inc. | $43,866,000 | -11.4% | 1,565,529 | +10.4% | 8.09% | +62.5% |
| TIL | New | Instil Bio Inc | $38,975,000 | – | 1,554,025 | +100.0% | 7.19% | – |
| STRO | Sutro BioPharma Inc | $38,136,000 | +4.8% | 1,675,579 | 0.0% | 7.03% | +92.3% | |
| NVAX | New | Novavax, Inc.call | $36,008,000 | – | 198,600 | +100.0% | 6.64% | – |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $25,770,000 | +192.3% | 1,022,612 | -25.0% | 4.75% | +435.9% |
| BOLT | New | Bolt Biotherapeutics, Inc | $24,270,000 | – | 737,459 | +100.0% | 4.48% | – |
| ALLK | Allakos Inc | $16,788,000 | -18.0% | 146,259 | 0.0% | 3.10% | +50.4% | |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $14,787,000 | +48.3% | 640,688 | +58.7% | 2.73% | +171.9% |
| SYRS | Syros Pharmaceuticals Inc | $14,769,000 | -32.4% | 2,189,199 | 0.0% | 2.72% | +24.0% | |
| ISEE | Iveric Bio, Inc. | $14,664,000 | -10.6% | 2,372,476 | 0.0% | 2.70% | +64.0% | |
| SWTX | Sell | Springworks Therapeutics Inc | $12,496,000 | -34.4% | 169,852 | -35.3% | 2.30% | +20.4% |
| TERN | New | Terns Pharmaceuticals, Inc | $10,946,000 | – | 497,555 | +100.0% | 2.02% | – |
| ALLK | New | Allakos Inccall | $9,527,000 | – | 83,000 | +100.0% | 1.76% | – |
| DBTX | New | Decibel Therapeutics Inc | $9,388,000 | – | 826,422 | +100.0% | 1.73% | – |
| VRNA | Verona Pharma PLC.spons ads | $9,289,000 | +19.4% | 1,111,112 | 0.0% | 1.71% | +119.1% | |
| CVAC | CureVac N.V. | $8,718,000 | +12.8% | 95,318 | 0.0% | 1.61% | +106.9% | |
| VIRX | New | Viracta Therapeutics Inc | $7,693,000 | – | 831,625 | +100.0% | 1.42% | – |
| AGLE | Aeglea BioTherapeutics, Inc. | $6,999,000 | +0.6% | 883,720 | 0.0% | 1.29% | +84.7% | |
| BCEL | Sell | Atreca Inc | $6,083,000 | -20.7% | 396,835 | -16.4% | 1.12% | +45.5% |
| BCTG | BCTG Acquisition Corp | $5,560,000 | -2.8% | 500,000 | 0.0% | 1.02% | +78.3% | |
| EQ | Sell | Equillium, Inc. | $5,465,000 | -4.9% | 764,403 | -28.8% | 1.01% | +74.4% |
| NVAX | Novavax, Inc. | $5,468,000 | +62.6% | 30,160 | 0.0% | 1.01% | +198.2% | |
| JYAC | Buy | Jiya Acquisition Corp | $4,989,000 | -99.0% | 507,041 | +9607.8% | 0.92% | -98.2% |
| AVDL | Buy | Avadel Pharmaceuticals PLCspons adr | $4,965,000 | +71.1% | 549,250 | +26.5% | 0.92% | +213.7% |
| KRON | Kronos Bio Inc | $4,866,000 | -2.0% | 166,250 | 0.0% | 0.90% | +79.8% | |
| EYPT | New | Eyepoint Pharmaceuticals Inc | $4,572,000 | – | 450,000 | +100.0% | 0.84% | – |
| RYTM | Rhythm Pharmaceuticals Inc | $4,276,000 | -28.5% | 201,046 | 0.0% | 0.79% | +31.3% | |
| ALPN | Alpine Immune Sciences Inc | $4,231,000 | -15.9% | 399,190 | 0.0% | 0.78% | +54.2% | |
| KALA | Kala Pharmaceuticals Inc | $4,052,000 | -0.6% | 601,162 | 0.0% | 0.75% | +82.2% | |
| VTGN | Buy | Vistagen Therapeutics Inc | $3,901,000 | +22.6% | 1,831,490 | +11.7% | 0.72% | +124.7% |
| ALBO | Albireo Pharma, Inc. | $3,525,000 | -6.0% | 100,000 | 0.0% | 0.65% | +72.4% | |
| IMCR | New | Immunocore Holdings Limitedspons ads | $3,406,000 | – | 80,000 | +100.0% | 0.63% | – |
| BLSA | BCLS Acquisition Corp | $3,171,000 | -5.1% | 300,000 | 0.0% | 0.58% | +74.1% | |
| CHFWU | Consonance HFW Acquisition Co | $2,928,000 | -6.8% | 300,000 | 0.0% | 0.54% | +70.9% | |
| RCKT | Rocket Pharmaceuticals Inc | $2,829,000 | -19.1% | 63,770 | 0.0% | 0.52% | +48.3% | |
| ODT | Sell | Odonate Therapeutics Inc | $2,395,000 | -84.7% | 700,421 | -14.1% | 0.44% | -71.9% |
| LSAQ | Lifesci Acquisition II Corp | $2,028,000 | -5.0% | 200,000 | 0.0% | 0.37% | +74.0% | |
| ALVR | Allovir, Inc | $1,927,000 | -39.1% | 82,336 | 0.0% | 0.36% | +11.6% | |
| BNTX | BioNTech SEspons ads | $1,179,000 | +34.0% | 10,795 | 0.0% | 0.22% | +146.6% | |
| NGM | NGM Biopharmaceuticals, Inc. | $530,000 | -4.0% | 18,225 | 0.0% | 0.10% | +75.0% | |
| Sell | Catabasis Pharmaceuticals Inc | $434,000 | -32.4% | 150,000 | -50.0% | 0.08% | +23.1% | |
| AMRN | Amarin Corp PLCspons adr new | $155,000 | +27.0% | 25,000 | 0.0% | 0.03% | +141.7% | |
| KDMN | Exit | Kadmon Hldgs Inc | $0 | – | -165,000 | -100.0% | -0.07% | – |
| SBTX | Exit | Silverback Therapeutics Inc | $0 | – | -25,000 | -100.0% | -0.12% | – |
| KALV | Exit | KalVista Pharmaceuticals Inc | $0 | – | -67,270 | -100.0% | -0.13% | – |
| HOOK | Exit | Hookipa Pharma Inc | $0 | – | -129,660 | -100.0% | -0.14% | – |
| GERN | Exit | Genron Corporation | $0 | – | -1,224,870 | -100.0% | -0.20% | – |
| FULC | Exit | Fulcrum Therapeutics, Inc. | $0 | – | -294,118 | -100.0% | -0.35% | – |
| PANAU | Exit | Panacea Acquisition Corp.unit | $0 | – | -400,000 | -100.0% | -0.51% | – |
| COGT | Exit | Cogent Biosciences Inc | $0 | – | -588,961 | -100.0% | -0.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.